Nektar Therapeutics (NKTR) CAO Jillian B. Thomsen Sells 2,545 Shares

Nektar Therapeutics (NASDAQ:NKTR) CAO Jillian B. Thomsen sold 2,545 shares of the business’s stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $82.94, for a total value of $211,082.30. The transaction was disclosed in a filing with the SEC, which is available through this link.

Nektar Therapeutics (NASDAQ NKTR) opened at $83.45 on Wednesday. Nektar Therapeutics has a 1-year low of $12.50 and a 1-year high of $99.02. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91. The stock has a market capitalization of $13,381.02, a price-to-earnings ratio of -115.90 and a beta of 2.04.

Several hedge funds have recently modified their holdings of the business. BlackRock Inc. lifted its holdings in shares of Nektar Therapeutics by 2.1% in the 4th quarter. BlackRock Inc. now owns 21,431,388 shares of the biopharmaceutical company’s stock worth $1,279,883,000 after buying an additional 431,269 shares during the period. State Street Corp lifted its holdings in shares of Nektar Therapeutics by 11.3% in the 2nd quarter. State Street Corp now owns 4,408,270 shares of the biopharmaceutical company’s stock worth $86,179,000 after buying an additional 447,023 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Nektar Therapeutics by 87.8% in the 3rd quarter. Janus Henderson Group PLC now owns 3,329,281 shares of the biopharmaceutical company’s stock worth $79,903,000 after buying an additional 1,556,352 shares during the period. First Trust Advisors LP lifted its holdings in shares of Nektar Therapeutics by 3.0% in the 4th quarter. First Trust Advisors LP now owns 1,705,632 shares of the biopharmaceutical company’s stock worth $101,860,000 after buying an additional 49,422 shares during the period. Finally, Geode Capital Management LLC lifted its holdings in shares of Nektar Therapeutics by 1.0% in the 4th quarter. Geode Capital Management LLC now owns 1,445,971 shares of the biopharmaceutical company’s stock worth $86,353,000 after buying an additional 13,958 shares during the period. Institutional investors and hedge funds own 96.23% of the company’s stock.

Several equities analysts have recently weighed in on NKTR shares. Canaccord Genuity reissued a “buy” rating and set a $80.00 target price (up previously from $50.00) on shares of Nektar Therapeutics in a research report on Wednesday, January 10th. Mizuho boosted their price objective on Nektar Therapeutics from $30.00 to $45.00 and gave the company a “buy” rating in a report on Tuesday, November 14th. Jefferies Group restated a “buy” rating and set a $35.00 price objective on shares of Nektar Therapeutics in a report on Wednesday, November 8th. JPMorgan Chase & Co. restated a “buy” rating and set a $44.00 price objective on shares of Nektar Therapeutics in a report on Monday, November 13th. Finally, Zacks Investment Research cut Nektar Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, January 9th. Three investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Nektar Therapeutics has a consensus rating of “Buy” and a consensus price target of $46.17.

WARNING: “Nektar Therapeutics (NKTR) CAO Jillian B. Thomsen Sells 2,545 Shares” was posted by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://stocknewstimes.com/2018/02/21/nektar-therapeutics-nktr-cao-jillian-b-thomsen-sells-2545-shares.html.

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply